Abstract:Introduction Agitation is reported in up to 70% of individuals with Alzheimer's disease (AD) and is characterized by emotional distress, aggressive behaviors, disruptive irritability and disinhibition. Agitation is associated with increased caregiver burden, decreased functioning, accelerated cognitive decline, earlier nursing home placement, and increased mortality. AXS-05 (dextromethorphan-bupropion) is a novel, oral NMDA receptor antagonist and sigma-1 receptor agonist approved for the treatment of major depressive disorder and under evaluation for Alzheimer's disease-related agitation (ADA). Methods ACCORD (Assessing Clinical Outcomes in Alzheimer's Disease Agitation; NCT04797715) was a Phase 3, randomized, discontinuation, double-blind, placebo-controlled, multi-center trial to evaluate efficacy and safety of AXS-05 in individuals with ADA. Participants with a diagnosis of probable AD and clinically meaningful agitation were enrolled into a 9-week, open-label period during which they were treated with AXS-05 and monitored for sustained clinical response defined as a ≥30% improvement from baseline in the Cohen Mansfield Agitation Inventory (CMAI) total score and improvement on the Patient Global Impression of Change (PGI-C; score of ≤3) that were both maintained for at least 4 consecutive weeks. Participants who experienced a sustained clinical response during the open-label period were then randomized (1:1) to continue treatment with AXS-05 or placebo in a double-blind fashion for up to 26 weeks. Treatment was continued until either a relapse of agitation symptoms or the end of the double-blind period, whichever occurred first. The primary endpoint in the study was time from randomization to relapse of agitation. The key secondary endpoint was the percentage of participants who relapsed. Results 178 individuals were enrolled into the open-label period and treated with AXS-05 (mean CMAI total score at baseline = 70.9). Statistically significant improvement on the CMAI was seen with open-label AXS-05 treatment at all timepoints starting at Week 1 (P<.001) with mean reductions from baseline of 6.7 points at Week 1 and 20.6 points at Week 5 (P<.001). In the randomized discontinuation phase of the trial, 108 participants were randomized to continue AXS-05 (n=53) or switched to placebo (n=55). AXS-05 met the primary endpoint by substantially delaying the time to relapse of agitation symptoms as compared to placebo, with a hazard ratio for time to relapse of 0.275 (P=.014), representing a 3.6-fold lower risk of relapse compared to placebo. AXS-05 also met the key secondary endpoint of relapse prevention (7.5% relapse incidence rate for AXS-05; 25.9% for placebo, P=.018). The rates of adverse events observed in the double-blind period were 28.3% AXS-05, 22.2% placebo. Discontinuations due to adverse events were 0% AXS-05, 1.9% placebo. There was no evidence of cognitive decline for participants treated with AXS-05. AXS-05 was not associated with sedation. Conclusions ACCORD met its primary outcome as treatment with AXS-05 substantially reduced the risk of relapse and was generally well-tolerated for participants who achieved sustained clinical response in the preceding open label treatment period. These data support the continued development of AXS-05 as an efficacious and safe novel treatment for ADA.

Successful Clonazepam Treatment of Neuroleptic‐Induced Akathisia in Older Adolescents and Young Adults: A Double‐Blind, Placebo‐Controlled Study

Trazodone as an Alternative Treatment for Neuroleptic-Associated Akathisia: A Placebo-Controlled, Double-Blind, Clinical Trial

Alternative treatment in adolescent with anti-NMDA receptor encephalitis catatonia

Evaluation of akathisia in patients receiving selective serotonin reuptake inhibitors/serotonin and noradrenaline reuptake inhibitors

Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia

Nocturnal akathisia in parkinson's disease: Treatment with clozapine

Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study

Electroconvulsive Therapy and Akathisia

Comparative Efficacy of Akathisia Treatments: A Network Meta-Analysis

Efficacy and Safety Of AXS-05 in Agitation Associated with Alzheimer's Disease: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Trial

Comparative Studies of Pharmacotherapy for School Refusal

1018 Minimal Effect of Long-Term Clonazepam on Cognitive Function in Patients with Isolated RBD

Ziprasidone, Haloperidol and Clonazepam Intramuscular Administration in the Treatment of Agitation Symptoms in Chinese Patients with Schizophrenia: A Network Meta-Analysis

0687 RLS Treatment Reduces Nighttime Agitation and Increases Sleep Duration in Older Adults with Alzheimer's Disease

An explicitly correlated second order Møller-Plesset theory using a frozen Gaussian geminal.

A Proposed Algorithm for the Pharmacological Treatment of Generalized Anxiety Disorder in the Older Patient

A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder

A Multicenter Study of Risperidone Treatment for Acute Agitation in Patients with Schizophrenia

Citalopram for agitation in Alzheimer's disease: design and methods

Computational Prediction of the Protonation Sites of Ac-Lys-(Ala)n-Lys-NH2 Peptides through Conceptual DFT Descriptors

Non-pharmacological Treatment for Elderly Individuals With Insomnia: A Systematic Review and Network Meta-Analysis